StageZero Life Sciences Ltd
14.3.2022 16:27:02 CET | ACCESS Newswire | Press release
This release replaces and corrects the release that was issued earlier this morning
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692951/CORRECTING-AND-REPLACING-StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Names Matthew H. DeFeo as Senior Vice President of Sales, Training and Recruiting15.9.2026 00:00:00 CEST | Press release
Accomplished Power Tools and Outdoor Power Equipment industry leader brings decades of experience in sales leadership, talent recruitment and development, channel management, and key account alignment NAPERVILLE, IL / ACCESS Newswire / September 14, 2026 / Matthew DeFeo joins Chervon as Senior Vice President of Sales, Training, and Recruiting effective September 14, 2026, reporting to CEO Joe Galli. Matthew DeFeo brings more than four decades of experience in the power tool and outdoor power equipment industry. He has an exceptional track record in building and leading large sales organizations, channel marketing teams, and training and development teams. DeFeo is widely recognized as a world-class leader in the campus recruiting of high potential graduates. He has built out impressive in-store sales coverage teams, end user marketing teams, campus recruiting teams, and training teams with an intense focus on key account alignment. A hallmark of DeFeo's remarkable career is his mentors
Chervon Names Jeffrey P. Campbell Senior Vice President of Industrial Commercial Sales14.9.2026 23:50:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / September 14, 2026 / Jeffrey P. Campbell joins Chervon as Senior Vice President of Industrial Commercial Sales effective Monday, September 14, 2026, reporting to CEO Joe Galli. Campbell joins Chervon with 25 years of exceptional executive leadership experience in the professional tool industry. He has built and led high-performance sales and channel marketing teams, developed strategic key account partnerships and has consistently driven strong growth across all professional and automotive channels of distribution. In his new role, Campbell will lead Chervon's Industrial / Commercial Sales network serving the many professional and automotive tool channels. "Jeff brings an impressive and unmatched combination of professional and automotive channel sales leadership, channel management, customer partnership skills and organizational development," said Joe Galli, CEO of Chervon. "His exhaustive command of our channels, key accounts, and users, combined wi
AGFA HealthCare Puts Clinical Attention at the Center of Enterprise Imaging at RSNA 202614.9.2026 16:30:00 CEST | Press release
One unified Enterprise Imaging platform brings workflow, streaming, cloud, and AI together to help clinicians stay focused and imaging organizations reduce complexity. CARLSTADT, NJ / ACCESS Newswire / September 14, 2026 / "Clinical attention has become one of healthcare's most valuable resources. The technology surrounding clinicians should preserve focus, not compete for it," said Nathalie McCaughley, President, AGFA HealthCare. "At RSNA 2026, we're showing how Enterprise Imaging continues to evolve around one consistent clinical experience. By bringing workflow, intelligence, and information together around how clinicians naturally work, we can reduce friction and help keep clinical attention where it matters most." At RSNA 2026, AGFA HealthCare will demonstrate how a unified approach to Enterprise Imaging can help healthcare organizations address a growing challenge: imaging volumes and clinical complexity continue to increase, while radiologists and imaging teams are being asked t
Litum Expands PathAware from Collision Warning to Forklift Safety Intelligence14.9.2026 08:00:00 CEST | Press release
PathAware® now turns collision risks, near misses and operator activity into actionable safety intelligence, while adding operator control, digital inspections and utilization insights, all through a retrofit system built for mixed forklift fleets. BOSTON, MA / ACCESS Newswire / September 14, 2026 / Litum today announced PathAware® IQ and PathAware® IQ+, expanding its forklift collision warning technology into a connected safety intelligence platform. PathAware IQ not only warns operators when risks occur. It captures safety events across the fleet and turns them into visual dashboards and actionable data, giving safety teams visibility into recurring risks, near misses, operators, vehicles, areas and shifts. This allows organizations to move from reacting to incidents to identifying patterns earlier, targeting operator training, addressing recurring hazards and measuring whether safety actions are actually working. PathAware IQ+ builds on that intelligence with digital pre-operation i
Surmodics Opens Medical Device Coating Capabilities in Ireland10.9.2026 16:00:00 CEST | Press release
The Galway Facility Brings Nearly 50 Years of Coating Expertise, Cleanroom Coating Services and Analytical Testing Closer to Medical Device Manufacturers Across Ireland and Europe BALLINASLOE, COUNTY GALWAY, IRELAND / ACCESS Newswire / September 10, 2026 / Surmodics, Inc. today announced its expanded medical device coating capabilities in Galway, Ireland, expanding access to the company's Performance Coatings and coating services for medical device manufacturers throughout Ireland and Europe. The facility now includes dedicated cleanroom environments designed for medical device coating services and brings Surmodics' nearly 50 years of coating experience closer to one of the world's leading medical technology hubs. "Ireland is home to a significant concentration of medical device manufacturers and technology innovators, making it an important market for Surmodics and our customers," said Damien Kilcommons, Vice President of Site Operation at the Ireland facility. "By establishing dedica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom